Status: Not yet recruiting
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
This is a single-institution, phase 2 trial of zanzalintinib plus investigator-choice bone-strengthening agent in patients with metastatic renal cell carcinoma (RCC) with bone metastases whose disease has advanced on 1-3 prior lines of therapy, including at least one immune oncology-based (IO) therapy in the adjuvant or first-line metastatic setting.
Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Kelly Fitzgerald, MDUpdated: May 1, 2026Locations: 1
Eligibility criteria
Participants must have unresectable advanced or metastatic RCC with a predominan... [+26]
Prior treatment with zanzalintinib for RCC. [+38]